- Home
- SPPP vs CRDF Comparison
SPPP vs CRDF Comparison
Compare SPPP & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- CRDF
- Stock Information
- Founded
- SPPP 2011
- CRDF 1999
- Country
- SPPP Canada
- CRDF United States
- Employees
- SPPP N/A
- CRDF N/A
- Industry
- SPPP
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPPP
- CRDF Health Care
- Exchange
- SPPP NYSE
- CRDF Nasdaq
- Market Cap
- SPPP 172.2M
- CRDF 169.6M
- IPO Year
- SPPP N/A
- CRDF N/A
- Fundamental
- Price
- SPPP $11.28
- CRDF $3.18
- Analyst Decision
- SPPP
- CRDF Strong Buy
- Analyst Count
- SPPP 0
- CRDF 4
- Target Price
- SPPP N/A
- CRDF $12.25
- AVG Volume (30 Days)
- SPPP 183.3K
- CRDF 1.2M
- Earning Date
- SPPP 01-01-0001
- CRDF 08-07-2025
- Dividend Yield
- SPPP N/A
- CRDF N/A
- EPS Growth
- SPPP N/A
- CRDF N/A
- EPS
- SPPP N/A
- CRDF N/A
- Revenue
- SPPP N/A
- CRDF $587,000.00
- Revenue This Year
- SPPP N/A
- CRDF N/A
- Revenue Next Year
- SPPP N/A
- CRDF N/A
- P/E Ratio
- SPPP N/A
- CRDF N/A
- Revenue Growth
- SPPP N/A
- CRDF N/A
- 52 Week Low
- SPPP $8.55
- CRDF $2.01
- 52 Week High
- SPPP $11.39
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- SPPP 61.09
- CRDF 41.74
- Support Level
- SPPP $11.24
- CRDF $2.98
- Resistance Level
- SPPP $11.58
- CRDF $3.99
- Average True Range (ATR)
- SPPP 0.23
- CRDF 0.29
- MACD
- SPPP 0.01
- CRDF -0.08
- Stochastic Oscillator
- SPPP 59.32
- CRDF 5.34
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.